IL17A and ankylosing spondylitis: Overexpression of IL-17 in IBD plays a key role in the disease mechanism (33), and IL-17 has become a therapeutic target for multiple sclerosis, psoriasis, psoriatic arthritis, ankylosing spondylitis, rheumatoid arthritis, and IBD (34, 35).